Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
More News related to PGNX
- Progenics Announces Third Quarter 2009 Financial Results
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
- Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
- Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
- Needham Cuts Progenics (PGNX) to Hold Midday
More News related to Upgrades
- Bank of America Downgrades Autoliv (ALV) to Underperform
- Roth Capital Downgrades Alnylam Pharmaceuticals (ALNY) to Hold. Price Target Cut
- Jefferies & Co Downgrades Ciena Corp (CIEN) to Underperform
- UBS Downgrades Union Pacific (UNP) to Neutral, $67 Target
- KeyBanc Downgrades Autoliv Inc. (ALV) to Hold; Valuation Call
Lazard Capital upgrades Progenics Pharmaceutical (Nasdaq: PGNX) from Hold to Buy.
To see more analyst ratings on PGNX Click Here.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
